Natera Inc
NTRA234.310USD
-5.250-2.19%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
32.23BMarket Cap
LossP/E TTM
More Details of Natera Inc Company
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Natera Inc Info
Ticker SymbolNTRA
Company nameNatera Inc
IPO dateJul 02, 2015
CEOChapman (Steven Leonard)
Number of employees4424
Security typeOrdinary Share
Fiscal year-endJul 02
Address13011 Mccallen Pass
CityAUSTIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code78753
Phone16502499090
Websitehttps://www.natera.com/
Ticker SymbolNTRA
IPO dateJul 02, 2015
CEOChapman (Steven Leonard)
Company Executives of Natera Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Matthew Rabinowitz, Ph.D.
Dr. Matthew Rabinowitz, Ph.D.
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
2.28M
-40000.00%
Mr. Roelof Frederick Botha
Mr. Roelof Frederick Botha
Lead Independent Director
Lead Independent Director
1.23M
+149.00%
Mr. Jonathan Sheena
Mr. Jonathan Sheena
Co-Founder, Director
Co-Founder, Director
295.55K
+306.00%
Mr. Daniel A Rabinowitz
Mr. Daniel A Rabinowitz
Secretary, Chief Legal Officer
Secretary, Chief Legal Officer
157.89K
+6902.00%
Mr. John Fesko
Mr. John Fesko
President, Chief Business Officer
President, Chief Business Officer
86.09K
-2048.00%
Mr. Solomon Moshkevich
Mr. Solomon Moshkevich
President - Clinical Diagnostics
President - Clinical Diagnostics
52.10K
+14389.00%
Herman Rosenman, CPA
Herman Rosenman, CPA
Independent Director
Independent Director
17.38K
-48419.00%
Dr. Monica Bertagnolli, M.D.
Dr. Monica Bertagnolli, M.D.
Independent Director
Independent Director
6.22K
+93.00%
Mr. Steven Leonard (Steve) Chapman
Mr. Steven Leonard (Steve) Chapman
Chief Executive Officer, Director
Chief Executive Officer, Director
3.17K
-1245.00%
Mr. Michael Burkes Brophy
Mr. Michael Burkes Brophy
Chief Financial Officer
Chief Financial Officer
3.06K
-5063.00%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Matthew Rabinowitz, Ph.D.
Dr. Matthew Rabinowitz, Ph.D.
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
2.28M
-40000.00%
Mr. Roelof Frederick Botha
Mr. Roelof Frederick Botha
Lead Independent Director
Lead Independent Director
1.23M
+149.00%
Mr. Jonathan Sheena
Mr. Jonathan Sheena
Co-Founder, Director
Co-Founder, Director
295.55K
+306.00%
Mr. Daniel A Rabinowitz
Mr. Daniel A Rabinowitz
Secretary, Chief Legal Officer
Secretary, Chief Legal Officer
157.89K
+6902.00%
Mr. John Fesko
Mr. John Fesko
President, Chief Business Officer
President, Chief Business Officer
86.09K
-2048.00%
Mr. Solomon Moshkevich
Mr. Solomon Moshkevich
President - Clinical Diagnostics
President - Clinical Diagnostics
52.10K
+14389.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Insurance carriers
559.50M
94.48%
Laboratory and other partners
25.10M
4.24%
Patients
7.58M
1.28%
By RegionUSD
Name
Revenue
Proportion
United States
582.37M
98.34%
Europe, Middle East, India, Africa
6.01M
1.01%
Asia Pacific and Other
2.28M
0.39%
Americas, excluding U.S
1.52M
0.26%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Insurance carriers
559.50M
94.48%
Laboratory and other partners
25.10M
4.24%
Patients
7.58M
1.28%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.86%
T. Rowe Price Associates, Inc.
8.50%
JP Morgan Asset Management
6.96%
BlackRock Institutional Trust Company, N.A.
4.88%
Farallon Capital Management, L.L.C.
3.06%
Other
67.74%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.86%
T. Rowe Price Associates, Inc.
8.50%
JP Morgan Asset Management
6.96%
BlackRock Institutional Trust Company, N.A.
4.88%
Farallon Capital Management, L.L.C.
3.06%
Other
67.74%
Shareholder Types
Shareholders
Proportion
Investment Advisor
45.64%
Investment Advisor/Hedge Fund
26.75%
Hedge Fund
12.65%
Individual Investor
3.02%
Family Office
2.73%
Family Office
2.73%
Family Office
2.44%
Bank and Trust
2.00%
Research Firm
1.59%
Other
0.46%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
1250
128.97M
92.69%
-4.03M
2025Q3
1200
128.93M
93.94%
-2.81M
2025Q2
1137
131.96M
96.64%
-402.16K
2025Q1
1129
133.60M
97.90%
+2.21M
2024Q4
1001
128.40M
95.17%
-537.76K
2024Q3
896
125.06M
100.75%
-6.81M
2024Q2
850
125.13M
101.89%
-7.92M
2024Q1
798
124.30M
101.71%
-6.12M
2023Q4
781
119.55M
99.60%
-13.66M
2023Q3
787
122.52M
102.97%
-5.30M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
12.33M
8.86%
-289.81K
-2.30%
Sep 30, 2025
T. Rowe Price Associates, Inc.
11.82M
8.5%
-247.47K
-2.05%
Sep 30, 2025
JP Morgan Asset Management
9.68M
6.96%
+763.30K
+8.56%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
6.79M
4.88%
+10.26K
+0.15%
Sep 30, 2025
Farallon Capital Management, L.L.C.
4.25M
3.06%
-568.36K
-11.79%
Sep 30, 2025
State Street Investment Management (US)
3.39M
2.44%
+72.09K
+2.17%
Sep 30, 2025
Duquesne Family Office LLC
3.21M
2.31%
+129.34K
+4.19%
Sep 30, 2025
Geode Capital Management, L.L.C.
2.60M
1.87%
+44.23K
+1.73%
Sep 30, 2025
Franklin Advisers, Inc.
2.58M
1.85%
+643.69K
+33.29%
Sep 30, 2025
Wellington Management Company, LLP
2.56M
1.84%
-77.63K
-2.95%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Franklin Genomic Advancements ETF
7.74%
Alger Weatherbie Enduring Growth ETF
7.06%
ARK Genomic Revolution ETF
4.98%
VanEck Biotech ETF
4.85%
First Trust Nasdaq Lux Digi Health Solutions ETF
4.74%
Global X Genomics & Biotechnology ETF
4.61%
TrueShares Technology, AI & Deep Learning ETF
4.02%
First Trust NYSE Arca Biotechnology Index Fund
3.95%
Invesco Dorsey Wright Healthcare Momentum ETF
3.85%
Strategas Macro Momentum ETF
3.57%
View more
Franklin Genomic Advancements ETF
Proportion7.74%
Alger Weatherbie Enduring Growth ETF
Proportion7.06%
ARK Genomic Revolution ETF
Proportion4.98%
VanEck Biotech ETF
Proportion4.85%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion4.74%
Global X Genomics & Biotechnology ETF
Proportion4.61%
TrueShares Technology, AI & Deep Learning ETF
Proportion4.02%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.95%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion3.85%
Strategas Macro Momentum ETF
Proportion3.57%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Natera Inc?
The top five shareholders of Natera Inc are:
The Vanguard Group, Inc. holds 12.33M shares, accounting for 8.86% of the total shares.
T. Rowe Price Associates, Inc. holds 11.82M shares, accounting for 8.50% of the total shares.
JP Morgan Asset Management holds 9.68M shares, accounting for 6.96% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.79M shares, accounting for 4.88% of the total shares.
Farallon Capital Management, L.L.C. holds 4.25M shares, accounting for 3.06% of the total shares.
The Vanguard Group, Inc. holds 12.33M shares, accounting for 8.86% of the total shares.
T. Rowe Price Associates, Inc. holds 11.82M shares, accounting for 8.50% of the total shares.
JP Morgan Asset Management holds 9.68M shares, accounting for 6.96% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.79M shares, accounting for 4.88% of the total shares.
Farallon Capital Management, L.L.C. holds 4.25M shares, accounting for 3.06% of the total shares.
What are the top three shareholder types of Natera Inc?
The top three shareholder types of Natera Inc are:
The Vanguard Group, Inc.
T. Rowe Price Associates, Inc.
JP Morgan Asset Management
The Vanguard Group, Inc.
T. Rowe Price Associates, Inc.
JP Morgan Asset Management
How many institutions hold shares of Natera Inc (NTRA)?
As of 2025Q4, 1250 institutions hold shares of Natera Inc, with a combined market value of approximately 128.97M, accounting for 92.69% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.25%.
What is the biggest source of revenue for Natera Inc?
In FY2025Q3, the Insurance carriers business generated the highest revenue for Natera Inc, amounting to 559.50M and accounting for 94.48% of total revenue.
